Bessemer Group Inc. Has $129,000 Stock Position in West Pharmaceutical Services, Inc. $WST

Bessemer Group Inc. decreased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 45.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 589 shares of the medical instruments supplier’s stock after selling 486 shares during the quarter. Bessemer Group Inc.’s holdings in West Pharmaceutical Services were worth $129,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. DAVENPORT & Co LLC boosted its holdings in shares of West Pharmaceutical Services by 103.8% during the first quarter. DAVENPORT & Co LLC now owns 2,230 shares of the medical instruments supplier’s stock worth $499,000 after purchasing an additional 1,136 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 85 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of West Pharmaceutical Services by 1,459.5% during the 1st quarter. Teacher Retirement System of Texas now owns 10,589 shares of the medical instruments supplier’s stock valued at $2,371,000 after acquiring an additional 9,910 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in shares of West Pharmaceutical Services by 10.8% during the 1st quarter. IFM Investors Pty Ltd now owns 14,523 shares of the medical instruments supplier’s stock valued at $3,251,000 after acquiring an additional 1,414 shares in the last quarter. Finally, Penserra Capital Management LLC grew its holdings in shares of West Pharmaceutical Services by 18.2% during the 1st quarter. Penserra Capital Management LLC now owns 891 shares of the medical instruments supplier’s stock valued at $199,000 after acquiring an additional 137 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

WST has been the topic of several research reports. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Barclays raised their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, October 27th. Rothschild & Co Redburn assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, September 15th. They set a “buy” rating and a $311.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $345.00 price objective on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, UBS Group lifted their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $349.20.

West Pharmaceutical Services Trading Up 2.6%

Shares of WST stock opened at $286.92 on Wednesday. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $264.59 and its two-hundred day moving average is $238.60. The company has a market cap of $20.64 billion, a PE ratio of 42.51, a price-to-earnings-growth ratio of 4.09 and a beta of 1.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.85 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Equities analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.